美泊利珠单抗对重症嗜酸性哮喘气道重塑与炎症的影响
这项前瞻性研究纳入37例符合美泊利珠单抗治疗条件的重症嗜酸性哮喘成人患者,每4周皮下注射100 mg美泊利珠单抗治疗12个月。结果显示美泊利珠单抗在改善哮喘控制和支气管舒张前FVC、减少急性加重、口服激素疗程及住院的同时,还减轻了气道重塑和炎症。
要点
- 美泊利珠单抗治疗12个月可改善哮喘控制、提高支气管舒张前FVC并减少急性加重、口服激素疗程和住院。
- 治疗6个月和12个月时支气管黏膜网状基底膜厚度、气道平滑肌质量和增殖细胞核抗原阳性平滑肌细胞均显著降低。
- 治疗6个月和12个月时BAL液中tenascin-C降低,12个月时fibulin-1降低,血嗜酸性粒细胞显著减少。
核心结论
- 美泊利珠单抗除抗炎作用外,还可能减轻重症嗜酸性哮喘的结构性气道改变,从而有助于其临床获益。
研究设计与样本
- 前瞻性研究纳入37例符合美泊利珠单抗治疗条件的重症嗜酸性哮喘成人患者,每4周皮下注射100 mg美泊利珠单抗,持续12个月。
- 在基线、6个月和12个月进行支气管活检和支气管肺泡灌洗,评估临床和功能结局、气道重塑及炎症标志物。
主要发现
- 12个月时美泊利珠单抗改善哮喘控制和支气管舒张前FVC,并减少急性加重次数、口服糖皮质激素疗程和住院。
- 治疗6个月和12个月时支气管黏膜网状基底膜厚度(P < 0.0001)、气道平滑肌质量(P = .0066)和增殖细胞核抗原阳性平滑肌细胞(P < .0001)均减少。
- BAL液中tenascin-C在6个月和12个月时降低,fibulin-1在12个月时降低;血嗜酸性粒细胞计数显著下降(P < .0001),12个月时BAL液中嗜酸性粒细胞几乎完全耗竭(P = .023)。
- 黏膜下嗜酸性粒细胞减少程度较小(P = .063)。
关键数值与推荐
- 美泊利珠单抗100 mg每4周皮下注射一次,持续12个月。
- 12个月时网状基底膜厚度P < 0.0001,气道平滑肌质量P = .0066,增殖细胞核抗原阳性平滑肌细胞P < .0001。
- 12个月时血嗜酸性粒细胞计数P < .0001,BAL液嗜酸性粒细胞P = .023,黏膜下嗜酸性粒细胞P = .063。
临床怎么用
- 对于符合美泊利珠单抗治疗条件的重症嗜酸性哮喘成人患者,该药在改善临床和功能结局的同时可能减轻气道重塑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: IL-5 is a key mediator of severe eosinophilic asthma (SEA) and also may contribute to airway remodeling. RESEARCH QUESTION: Can mepolizumab, an anti-IL-5 antibody, modify airway remodelling in adult patients with SEA? STUDY DESIGN AND METHODS: Thirty-seven patients who were eligible for mepolizumab were included prospectively. Mepolizumab 100 mg was administered subcutaneously every 4 weeks for 12 months. Bronchial biopsies and bronchoalveolar lavage (BAL) were performed at baseline, 6 months, and 12 months. Clinical and functional outcomes, airway remodeling, and inflammatory markers were assessed at each time point. RESULTS: At 12 months, mepolizumab was shown to improve asthma control and FVC before bronchodilation and reduce the number of exacerbations, oral corticosteroid courses, and hospitalizations. These clinical and functional improvements were associated with a reduction in reticular basement membrane thickness (P < 0.0001), airway smooth muscle (ASM) mass (P = .0066), and proliferating cell nuclear antigen-positive ASM cells (P < .0001) in the bronchial mucosa at both 6 and 12 months. BAL fluid showed reduced levels of tenascin-C at 6 and 12 months and of fibulin-1 at 12 months. Blood eosinophil counts decreased significantly (P < .0001), and eosinophils were almost completely depleted in BAL fluid (P = .023) at 12 months. Submucosal eosinophilia was reduced to a lesser extent (P = .063). INTERPRETATION: In addition to its antiinflammatory effects, mepolizumab also may attenuate structural airway changes in SEA, which could contribute to its clinical benefits. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT03797404; URL: www. CLINICALTRIALS: gov.
引用
- Taillé C, Hamidi F, Heddebaut N, et al. Impact of Mepolizumab on Airway Remodeling and Inflammation in Severe Eosinophilic Asthma. Chest. 2025. PMID: 41354402. doi:10.1016/j.chest.2025.10.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。